Essilor Stellest Earns TIME's Best Inventions 2026 Nod in Health & Wellness
Event summary
- Essilor® Stellest® lenses named one of TIME's Best Inventions of 2026 in Health & Wellness category.
- Lenses received FDA De Novo market authorization in September 2025 for slowing myopia progression in children.
- Essilor Stellest backed by clinical trials showing efficacy compared to single vision lenses.
- Nearly 5 billion people projected to be myopic by 2050, highlighting the growing need for myopia management solutions.
The big picture
EssilorLuxottica's TIME recognition underscores the strategic importance of myopia management in a market where childhood myopia is rising rapidly. With the FDA's backing and growing global awareness, Stellest lenses position EssilorLuxottica as a leader in evidence-based vision care solutions. The company's ability to sustain this momentum will depend on its execution in scaling production and expanding its partner network.
What we're watching
- Market Expansion
- How EssilorLuxottica will leverage TIME's recognition to accelerate global adoption of Stellest lenses.
- Regulatory Dynamics
- Whether the FDA's Breakthrough Device designation will facilitate faster approvals for similar innovations.
- Competitive Positioning
- The pace at which competitors develop comparable myopia management solutions.
